Categoria: Articoli in lingua originale

The American Diabetes Association has released its 2017 “Standards of Medical Care in Diabetes.” An overview of the group’s guidance on pharmacologic therapy for type 2 diabetes is available in the Annals of Internal Medicine. Among the recommendations: Metformin is still the preferred first-line regimen and should be prescribed for most

Teens and young adults with type 2 diabetes develop kidney, nerve, and eye diseases – as well as some risk factors for heart disease – more often than their peers with type 1 diabetes in the years shortly after diagnosis. The results are the latest findings of the SEARCH for Diabetes

How can an eating pattern that came about decades ago in the rural areas of the Mediterranean possibly be the diet of the future? Well, today it is no secret that the Mediterranean diet is the gold standard of diets. Not only because it has years of research supporting it,

The American Diabetes Association has issued a position statement for managing diabetic retinopathy, as published in Diabetes Care. The statement incorporates recent developments for diagnostic assessment and treatment options for clinicians and patients. These improvements include the widespread adoption of optical coherence tomography to assess retinal thickness and intraretinal pathology and wide-field

European regulators have approved Novo Nordisk’s fast acting insulin Fiasp for the treatment of diabetes in adults, as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via an insulin pump. Fiasp is an ultra-fast rapid-acting insulin that improves control of postprandial

Bruce Soloway, MD reviewing El-Khatib FH et al. Lancet 2016 Dec 19. Murphy HR and Stewart ZA. Lancet 2016 Dec 19. In a small trial, home use of the device improved glycemic control with minimal patient input. Currently available devices that link insulin pumps to continuous glucose monitors (CGMs) still require patients with diabetes to check

FDA has approved Abbott’s Freestyle Libre Pro System for professional continuous glucose monitoring (CGM), which provides clinicians with 14 days’ worth of patient data so they can make more informed clinical decisions regarding diabetes management. The system does not require finger-stick calibrations and is significantly more affordable than competitive CGM